EconDefense
ACQ-28 / Intellectual property and technology transfer

License federally owned inventions to commercialize technology

Obtain/protect federal patents and grant nonexclusive, exclusive or partially exclusive licenses, royalty-free or for consideration, while retaining government-use rights.

Authority / instrument · ACQ-28

Intellectual property & technology transfer

Intellectual property and technology transfer

Statute & instrument
Authority holder

Federal agency holding invention rights; authorized agency/laboratory licensing officials

What this does not authorize / hard limit

Technology-transfer duties and confidentiality provisions are not standalone financial assistance or commercial licensing powers; the award or license still uses its own operative authority.

Recorded executor

Laboratory ORTA, counsel and authorized agreement official

Continue to actor →

Recorded executing role; this record-specific route is not an additional institutional office.

Legal basisSources linkedLegal sources and instrument limits are recorded.
RequirementsGates recordedRead the requirements for this instrument; applicability depends on the proposed action.
Public fundingRules recordedLicense royalties/consideration per agreement; retention/distribution requires separate applicable authority such as 15 U.S.C. §3710c. Office budget figures are separate institutional context, not an allocation to this instrument.
Assigned rolesRoles recordedPublic sources describe institutional authority. The instrument identifies approval and execution roles; a specific signature remains transaction-dependent.
EngagementRelated evidenceA concrete application route with a commercialization plan, negotiated rights and royalty obligations. Program check: 2026-10-04; see each route for intake status.

Public evidence describes the institution and instrument; it is not approval of an individual transaction.

At a glance

Possible toolACQ-28 · Licensing & IP
Legal basis35 U.S.C. §207

Authority holder: Federal agency holding invention rights; authorized agency/laboratory licensing officials

Licensing & IP

Mechanism tags describe the source text; they do not expand the authority.

Availability and verification

Express statutory pathway; award-specific appropriations, available balances, delegations, implementation and approvals not independently verified.

Program process and intake

Checked 2026-10-04 · process documented. Program evidence is separate from legal authority, available funds and transaction approval.

A concrete application route with a commercialization plan, negotiated rights and royalty obligations.

Navy patent and software commercialization — NRL example

Who this route serves
Prospective commercial licensees of government technology
Administering office / routing lead
NRL Technology Transfer Office (Code 1004); Carderock has a separate TTO route
Related process

These are operational federal-technology licensing examples. The record’s 35 USC 207/209 conditions remain separate from an individual lab’s application instructions.

What this evidence label means
Application process published; terms negotiated

The published process was checked; no award or appointment availability is inferred.

Status reference date: 2026-10-04 · research checked 2026-10-04

NRL commercial licensing · Commercial Licenses; application and submission addressofficial program guidance · Evidence record

Program eligibility

  • NRL commercial licenses serve private-sector or mixed private/government markets; government-only sales are directed to its separate Government Purpose License process.

    NRL commercial licensing · Commercial Licenses; application and submission addressofficial program guidance · Evidence record

Steps and preparation

  • Select the technology and complete the Navy invention-license application; NRL publishes submission to its TTO, including nrltechtran@us.navy.mil.

    NRL commercial licensing · Commercial Licenses; application and submission addressofficial program guidance · Evidence record
  • The application asks for commercialization milestones, target availability, investment needs, manufacturing countries, and financial and technical ability to execute.

    Navy invention license application · Part III, item 14(a–c); form dated August 2018official program guidance · Evidence record
Funding, limits and authority relationship

Funding and financial terms

  • Negotiated license / royalty obligations · License-specific

    Carderock describes royalty and exclusivity terms as individually negotiated; licensing rights are not a grant to develop the product.

    Carderock Technology Transfer Office · Patent License Agreement; partnership contactofficial program guidance · Evidence record

Exclusions and limits

  • The government retains government-use rights. Commercialization objectives, investment plans and time-to-market are evaluated; a patent listing is not an automatic license.

    Carderock Technology Transfer Office · Patent License Agreement; partnership contactofficial program guidance · Evidence record

Authority relationship source

NRL commercial licensing · Commercial Licenses; application and submission addressofficial program guidance · Evidence record

Read the official process →

program information: Information and institutional inquiry, not an award application.

Research scope and sources checked

The first program-depth pass checked the cited program pages, notices and legal framework. Evidence is limited to the named routes and source-access notes; it does not establish every implementation of the statute.

What remains unverified

  • Availability of a particular invention, exclusive-license notices, negotiated rates and manufacturing exceptions require case-specific review.

A dated source check is not continuing monitoring. Recheck the linked official notice before preparing a submission. Browse program research →

Requirements and limits

Eligibility & prerequisites

  • Exclusive scope must be reasonably necessary for commercialization, support public interest and avoid anticompetitive effects.
  • Development/marketing plan; ordinarily substantial U.S. manufacturing; small-business preference if equally capable.
  • Federal laboratory technology-transfer responsibilities and ORTA assistance under §3710 support routing; invention information under §205 may be withheld for the reasonable period needed to protect patent rights and under its terms.

Limits & exclusions

  • Government retains paid-up license and termination protections.
  • Exclusive/partially exclusive license ordinarily requires 15-day public notice; CRADA invention exception applies.
  • Technology-transfer duties and confidentiality provisions are not standalone financial assistance or commercial licensing powers; the award or license still uses its own operative authority.

Funding conditions

  • License royalties/consideration per agreement; retention/distribution requires separate applicable authority such as 15 U.S.C. §3710c.

Read the funding and execution guide

Who contributes what

Need & planning

  • Laboratory scientific lead and Office of Research and Technology Applications

Resources

  • Laboratory director and sponsoring component budget owner

Approval

  • Laboratory director and agency approver as statute/delegation requires

Execution

  • Laboratory ORTA, counsel and authorized agreement official

Partners & review

  • Industry, universities, nonprofit and government collaborators within eligibility limits

Office links are editorial matches to the original role text, not verified delegations. Composite labels and unmatched actors are preserved.

Coordination pathway

ORTA identifies invention → IP counsel confirms government rights → commercialization and competition review → authorized licensing official.

Actor and execution-role sources

October 5 statutory review

Add adjacent duty and confidentiality context without inventing a separate financing or licensing instrument.

Section coverage and review findings

What this research establishes

Legal basisSources linkedLegal sources and instrument limits are recorded.
RequirementsGates recordedRead the requirements for this instrument; applicability depends on the proposed action.
Public fundingRules recordedLicense royalties/consideration per agreement; retention/distribution requires separate applicable authority such as 15 U.S.C. §3710c. Office budget figures are separate institutional context, not an allocation to this instrument.
Assigned rolesRoles recordedPublic sources describe institutional authority. The instrument identifies approval and execution roles; a specific signature remains transaction-dependent.
EngagementRelated evidenceA concrete application route with a commercialization plan, negotiated rights and royalty obligations. Program check: 2026-10-04; see each route for intake status.

Confidence: High on express authority and cited conditions; execution assignment is illustrative unless statute expressly names it.

Currentness: GovInfo 2024 Code (includes FY2025 NDAA, P.L. 118-159) read in full for cited provision; targeted FY2026 NDAA P.L. 119-60 amendment/repeal sweep. No claim of complete legislative currency through 2026-10-02; remaining 2026 delta needs counsel validation.

Review scope: Original research target October 2, 2026; no record-specific last-review date supplied. Publication is not legal-currentness certification.